AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 292 min read$ACAD

Kihara James sold $298K of ACAD

Kihara James (PRINCIPAL ACCOUNTING OFFICER) sold 11,421 shares of ACADIA PHARMACEUTICALS INC (ACAD) at $26.08 ($0.30M total) on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kihara James
Published Jun 29, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ACAD
Neutral
medium confidence
Mentioned
$ACAD
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACADNeutralLow
01

Why it matters

The disclosed open-market sale by the principal accounting officer is a new, primary-source datapoint, but the 10b5-1 pre-arranged nature limits interpretive impact.

02

Market read

Traders may briefly reassess sentiment around ACAD, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article lacks context on total planned volume, whether other insiders bought/sold, and whether the sale was part of a broader compensation/vesting schedule.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-29 after-hours; reflects sale executed 2026-06-26.

Background

The article is an SEC Form 4 insider transaction disclosure for Acadia Pharmaceuticals.

Company-level read

Ticker impact

$ACADNeutralMedium confidence
Context

Acadia Pharmaceuticals insider Kihara James (principal accounting officer) sold 11,421 shares at $26.0846 on a 10b5-1 plan, per Form 4.

Expected impact

Likely minimal near-term price impact; any effect should be short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 open-market sale under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution; traders may watch for follow-on sales or other insider buys.

Key entities

  • issuer
    ACADIA PHARMACEUTICALS INC

    US-listed company whose insider transaction is disclosed on Form 4.

  • insider
    Kihara James

    Principal accounting officer reporting an open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACAD insider trading history →

Related articles

AUG 28
$ACADHighAI 9/10

Did First-in-Class EU Approval for DAYBU Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?

Acadia Pharmaceuticals (ACAD) received EU approval for DAYBU to treat Rett syndrome, based on Phase 3 trial data. This is the first authorized therapy for Rett syndrome in the EU, potentially opening a new market. The company is now in pricing and reimbursement negotiations. ACAD raised 2026 DAYBU sales guidance to $480M-$510M, with analysts projecting up to $1.9B in revenue. The approval strengthens ACAD's long-term diversification but near-term success depends on country-specific outcomes.

simplywall.st2 min
AUG 16
$ACADHighAI 9/10

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (NASDAQ:ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. Management raised 2026 DAYBUE sales guidance to $480 million-$510 million and updated total revenue guidance to $1.24 billion-$1.30 billion. Cash and investments were $956 million as of June 30, 2026.

aol.com7 min
AUG 12
$ACADMed

Acadia Pharmaceuticals stock hits 52-week high at $29.81

Acadia Pharmaceuticals shares rose to a 52-week high around $29.76 to $29.81 and were about $29.77 at the time of reporting. The stock is up 36% over six months. Acadia reported Q2 2026 revenue of about $308 million versus a $296 million consensus, driven by Daybue sales of $125 million and steady Nuplazid. RBC, Oppenheimer, and Citizens raised price targets; analysts also cited upward earnings revisions and a Phase 2 RADIANT trial update.

investing.com4 min
AUG 12
$ACADMedAI 8/10

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. DAYBUE net sales were $125 million (+30%) and NUPLAZID net sales $183 million (+10%). 2026 sales guidance: DAYBUE $480-$510M, NUPLAZID $760-$790M, total revenue $1.24-$1.30B. Net income was $32M ($0.18/share).

fool.com7 min
AUG 6
$ACADMedAI 8/10

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

Acadia Pharmaceuticals (NASDAQ:ACAD) raised its 2026 DAYBUE net sales guidance to $480 million to $510 million from $460 million to $490 million, citing expected initial European commercial sales in Q4. The company said the EMA CHMP issued a positive opinion for trofinetide and expects an EC decision later in Q3. Acadia kept 2026 NUPLAZID guidance at $760 million to $790 million and reported $956 million cash.

yahoo.com6 min